IP Library › Patent Application 14329765
Patent Application
App. No. 14/329,765

METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/329,765
Abstract

Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.

Claims (10)

1 - 44 . (canceled)

45 . A single unit dosage form comprising a composition consisting essentially of at least 99.95% (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and less than 0.05% (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-amino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid based on total weight of the composition.

46 . The single unit dosage form of claim 45 , wherein the composition is a lyophilized powder.

47 . The single unit dosage form of claim 45 comprising sufficient (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to permit administration of doses of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid within the range of about 10-100 mg/m 2 .

48 . The single unit dosage form of claim 45 , wherein the dosage form is for intravenous administration.

49 . The single unit dosage form of claim 45 comprising about 1-50 mg of the composition.

50 . The single unit dosage form of claim 49 comprising about 25 mg of the composition.

51 . The single unit dosage form of claim 49 further comprising methanesulfonic acid.

52 . The single unit dosage form of claim 51 further comprising sorbitol.

53 . The single unit dosage form of claim 51 suitable for reconstitution with water to provide a liquid dosage form for intravenous administration.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Nov 5, 2020
From: WESTERN ALLIANCE BANK
To: SUNESIS PHARMACEUTICALS, INC.
Reel/Frame 054335/0429 →
SECURITY INTEREST Recorded May 10, 2016
From: SUNESIS PHARMACEUTICALS, INC.
To: WESTERN ALLIANCE BANK
Reel/Frame 038655/0493 →